Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Sécurité et efficacité du dispositif ENTERPRISE 2 dans le traitement endovasculaire des anévrismes intracrâniens (EMPOWER)

2 novembre 2026 mis à jour par: Medos International SARL

ENTERPRISE 2 Vascular Reconstruction Device and Delivery System Registry : une étude observationnelle multicentrique, prospective et à un seul bras pour évaluer la sécurité et l'efficacité du dispositif pour faciliter l'embolisation endovasculaire par bobine des anévrismes intracrâniens

The study is designed to evaluate the safety and effectiveness of ENTERPRISE 2 vascular reconstruction device and delivery system (hereinafter referred to as ENTERPRISE 2) to facilitate endovascular coil embolization of intracranial aneurysms.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

This is a prospective, multicenter, single-arm observational study, in which enrolled patients will be implanted with the ENTERPRISE 2 for evaluation of safety and effectiveness of ENTERPRISE 2 in real-world applications.

The study population will consist of 164 patients with ruptured or unruptured intracranial aneurysms and a parent vessel diameter of ≥2.5 mm and ≤4 mm. All patients will be implanted with the study device.

The enrolled patients will be followed at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure.

The primary endpoint is the incidence of aneurysm recanalization (at 180 days) evaluated through digital subtraction angiography (DSA). Secondary effectiveness endpoints include incidence of aneurysm recanalization (at 1 year), successful stent/coil placement rate (immediately post procedure), aneurysm occlusion (immediately post procedure, at 180 days and 1 year), incidence of retreatment (at 30 and 180 days, and 1, 2, 3, 4 and 5 years). Safety evaluation include: incidence of disabling stroke or neurological death (at 180 days and 1 year), incidence of in-stent thrombosis (at 180 days and 1 year), and incidence of in-stent stenosis (at 180 days and 1 year). Exploratory endpoints include stent wall apposition performance (intra-procedure), first-time deployment success rate (intra-procedure) and duration of stent deployment (intra-procedure).

Type d'étude

Observationnel

Inscription (Réel)

164

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100070
        • Beijing Tiantan Hospital, Capital Medical University
      • Beijing, Beijing Municipality, Chine, 100029
        • Beijing Anzhen Hospital, Capital Medical University
    • Guangdong
      • Guangzhou, Guangdong, Chine
        • Zhujiang Hospital of Southern Medical University
    • Henan
      • Zhengzhou, Henan, Chine, 450052
        • The first affiliated hospital of Zhengzhou university
    • Hubei
      • Wuhan, Hubei, Chine, 430022
        • Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210008
        • Nanjing Drum Tower Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 330006
        • The first affiliated hospital of Nanchang university
    • Liaoning
      • Shenyang, Liaoning, Chine, 110004
        • Shengjing Hospital of China Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine
        • Huashan Hospital Shanghai Medical college, Fudan University
    • Zhejiang
      • Hangzhou, Zhejiang, Chine, 310007
        • Zhejiang Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

This study will be conducted in patients with unruptured or ruptured intracranial aneurysm with a parent vessel diameter of ≥2.5 mm and ≤4 mm.

La description

Inclusion Criteria:

  1. Patient (or his/her legal representative) understands the nature of the procedure and provides voluntary written informed consent for the use of his/her peri-procedural and follow-up data;
  2. Aged between 18 years and 80 years of age the time of consent;
  3. Patient has been diagnosed with ruptured (Hunt-Hess Grade I-III) or unruptured intracranial aneurysm and requires the endovascular treatment;
  4. Parent vessel with a diameter of ≥2.5 mm and ≤4 mm;
  5. Patient is willing to return to the investigational site for the post-procedure follow-up evaluations.

Exclusion Criteria:

  1. Severe co-morbidity associated with a life-expectancy of less than twelve months as determined by the investigator;
  2. Poor clinical condition with modified Rankin Scale (mRS) score ≥4;
  3. Having prior or potential severe allergic reaction to contrast medium;
  4. Known allergies to any of the device components, including Enterprise 2 and PROWLER® SELECT™ Plus Infusion Catheter;
  5. Angiogram demonstrating that the aneurysm is not appropriate for endovascular treatment (i.e. severe intracranial vessel tortuosity, stenosis, intracranial vasospasm not responsive to medical therapy);
  6. Arteriovenous malformation (AVM) in the territory of the target aneurysm;
  7. Unsuitable for the antithrombotic and/or anticoagulant therapies;
  8. Implantation of an intracranial stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
  9. Implantation of a carotid stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
  10. Evidence of active infection;
  11. Pregnant or lactating women;
  12. Having participated in clinical studies of other investigational drugs or devices within 30 days prior to signature of Informed Consent Form, excluding epidemiological studies of observational nature or natural history or not involving intervention;
  13. Pre-planned staged procedure of target aneurysms.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
ENTERPRISE 2 group

The study population enrolled for this clinical study is "aneurysm patients who need stent-assisted coiling treatment", using ENTERPRISE 2 device.

The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of aneurysm recanalization
Délai: at 180 days post procedure

Incidence of aneurysm recanalization (at 180 days) = number of target aneurysm recanalization (at 180 days) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 180-day follow-up will be obtained through DSA, and the post-procedure immediate aneurysm recanalization shown in angiograms will be graded as per the Raymond-Roy Classification Scale.

The Raymond-Roy Classification at each follow-up time point increased by ≥ one class relative to that immediately after the procedure is defined as recanalization (e.g., Class I immediately after the procedure, Class II at 180-day follow-up).

at 180 days post procedure

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence of aneurysm recanalization
Délai: at 1 year post procedure

Incidence of aneurysm recanalization (at 1 year) = number of target aneurysm recanalization (at 1 year) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 1 year follow-ups will be obtained through DSA or MRA or CTA.

at 1 year post procedure
Successful stent/coil placement rate
Délai: immediately post procedure

Successful stent/coil placement rate = number of target aneurysms with successful stent/coil placement ÷ total number of target aneurysms× 100%.

Successful stent/coil placement is defined as successful stent deployment and successful delivery and placement of the coil at the target aneurysm assessed immediately post procedure through angiography.

immediately post procedure
Aneurysm occlusion
Délai: immediately post procedure, at 180 days and at 1 year post procedure

Aneurysm occlusion rate = number of target aneurysms with Raymond-Roy Class I or II aneurysm occlusion÷ total number of target aneurysms× 100%.

The aneurysm occlusion will be assessed by classifying the post-procedure immediate aneurysm occlusion shown in angiograms based on the Raymond-Roy Classification.

immediately post procedure, at 180 days and at 1 year post procedure
Incidence of retreatment
Délai: at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure

Incidence of retreatment = number of target aneurysms receiving retreatment during the follow-up ÷ total number of target aneurysms receiving follow-up ×100%.

Retreatment refers to any intervention to the target aneurysm after completing first stent-assisted coil embolization for the target aneurysm.

at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Incidence of disabling stroke or neurological death
Délai: at 180 days, at 1 year post procedure

Incidence of disabling stroke or neurological death = number of patients with disabling stroke or neurological death ÷ total number of patients receiving follow-up × 100%.

Stroke is defined as rapidly developing clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours with no apparent cause other than of vascular origin, including ischemic stroke or hemorrhagic stroke (i.e., intraparenchymal hemorrhage (IPH), SAH, subdural hemorrhage (SDH), epidural hemorrhage (EDH)).

Disabling stroke is defined as mRS score ≥ 3 assessed at a minimum of 90 days (+/- 30 days) post-stroke event.

Neurological death, also called brain death, refers to irreversible loss of the capacity for consciousness combined with the irreversible loss of all brainstem functions, including the capacity to breathe.

at 180 days, at 1 year post procedure
Incidence of in-stent thrombosis
Délai: at 180 days, at 1 year post procedure

Incidence of in-stent thrombosis = number of target aneurysms with parent vessel (in-stent) thrombosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%.

at 180 days, at 1 year post procedure
Incidence of in-stent stenosis
Délai: at 180 days, at 1 year post procedure

Incidence of in-stent stenosis = number of target aneurysms with parent vessel (in-stent) stenosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%.

Mild, moderate, and severe in-stent stenosis is clinically defined as a stenosis of <33%, 33-67%, and ≥67%, respectively, comparing with non-stented parent vessel [43, 44]. In this study, moderate and severe in-stent stenoses (with a stenosis of ≥33%) of the parent vessel are defined as in-stent stenosis.

at 180 days, at 1 year post procedure

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Xinjian Yang, Professor, Beijing Tiantan Hospital
  • Chercheur principal: Shiqing Mu, Professor, Beijing Tiantan Hospital
  • Chercheur principal: Qingrong Zhang, Professor, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  • Chercheur principal: Yuxiang Gu, Professor, Huashan Hospital Shanghai Medical college, Fudan University
  • Chercheur principal: Chuanzhi Duan, Professor, Southern Medical University, China
  • Chercheur principal: Shu Wan, Professor, Zhejiang Hospital
  • Chercheur principal: Bo Yu, Professor, Shengjing Hospital
  • Chercheur principal: Yang Wang, Professor, The First Affiliated Hospital of Nanchang University
  • Chercheur principal: Sheng Guan, Professor, The First Affiliated Hospital of Zhengzhou University
  • Chercheur principal: Wohua Zhao, Professor, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
  • Chercheur principal: Xinjian Yang, Professor, Beijing Anzhen Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 juillet 2020

Achèvement primaire (Réel)

22 avril 2022

Achèvement de l'étude (Réel)

26 juillet 2026

Dates d'inscription aux études

Première soumission

27 février 2020

Première soumission répondant aux critères de contrôle qualité

27 février 2020

Première publication (Réel)

28 février 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner